UNITED THERAPEUTICS Corp 8-K

What Happened

• On March 2, 2026, United Therapeutics Corporation announced positive results from the ADVANCE OUTCOMES clinical study of ralinepag in patients with pulmonary arterial hypertension (PAH). The company issued a press release and provided presentation slides to summarize the data.
• United Therapeutics hosted a webcast presentation to discuss the ADVANCE OUTCOMES results at 8:30 a.m. Eastern Time on March 2, 2026; the slides and a rebroadcast (available for one year) are posted at https://ir.unither.com/events-and-presentations.

Key Details

• Filing date: March 2, 2026 (Form 8-K, Item 7.01 Regulation FD Disclosure).
• Study: ADVANCE OUTCOMES — ralinepag in pulmonary arterial hypertension (PAH).
• Materials: Press release attached as Exhibit 99.1 and investor presentation slides as Exhibit 99.2 to the 8-K.
• Webcast: Live presentation 8:30 a.m. ET on March 2, 2026; rebroadcast available for one year on the company’s investor site.

Why It Matters

• The company publicly disclosed favorable clinical results for ralinepag, a drug candidate for PAH, and provided investor-accessible materials and a webcast to review the data. For investors, this is a material clinical development that may affect how the market values United Therapeutics’ PAH pipeline and upcoming regulatory or commercial milestones.